CEFALY Technology

CEFALY Technology makes the CEFALY device, an FDA-cleared, over-the-counter neuromodulation device worn on the forehead that delivers pulses to the trigeminal nerve. It has an Acute mode for treating migraine attacks and a Prevent mode for reducing future attacks. The CEFALY Migraine Relief app pairs with the device to control sessions and log attacks, triggers and treatments.

The device is sold to people with migraine as a prescription-free option that is HSA/FSA eligible, and the company offers a 90-day trial with one-on-one coaching and a refund option. The website states that the Veterans Health Administration made CEFALY the most frequently used neuromodulation device for migraine among veterans it serves. Clinical claims on the site cite the ACME, TEAM and PREMICE studies, including 79% of patients reporting a significant reduction in headache pain after one hour of Acute treatment.

The company was founded in Belgium in 2004 and opened its U.S. office in Darien, Connecticut in 2014. The website lists a Liege, Belgium location in its job openings and describes the company as based in Belgium and the U.S. Open roles include R&D, systems and integrations engineering, quality and regulatory affairs, operations and lifecycle marketing. Named leaders on the site are CEO Andy Page, CTO John Bradbury and CFO Vincent Denis.

Product: CEFALY neuromodulation device with Acute and Prevent modes for migraine, plus the CEFALY Migraine Relief companion app.